This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

US panel, finding no irreparable harm, vacates injunction against Sun Pharma

By Melissa Ritti ( May 7, 2025, 22:04 GMT | Insight) -- For the second day in a row, the US Court of Appeals for the Federal Circuit vacated what has become, in the so-called “eBay” era, an increasingly rare patent injunction. Today’s precedential ruling marks a win for Sun Pharmaceuticals, whose “extended” head start in the market for treating alopecia areata is “inevitable” given the “best-case scenario” of Incyte bringing to market its own autoimmune disorder drug and expected December 2026 patent expiration, the panel said.In a precedential decision, and for the second time in as many days, the court tasked with resolving all patent appeals in the US vacated a patent injunction....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections